Evolving Treatment Options and
Strategies in Multiple Sclerosis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2016 Fall Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from December 15, 2016 to December 31, 2017

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  To print or save your certificate, you will need to click on the “download” button and either print or save.

These presentations require Adobe Flash Player.  You can download it here.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
 AbbVie Inc, Sanofi Genzyme, and Teva Pharmaceuticals




Multiple Sclerosis (MS) is a chronic progressive disease and is the most common neurological cause of disability among young adults, with a prevalence of approximately 400,000 cases throughout the United States. Although there is still no cure for MS, many advances in MS treatment have arrived in recent years, allowing patients to manage these symptoms and improve their quality of life. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease. Over the past decade, there have been numerous revisions to MS diagnostic criteria and the development of multiple new and emerging therapies. While the explosion of these emerging therapies have shown the ability to improve outcomes and quality of life in patient's relapsing MS, it makes staying current with best practices a challenge that must be overcome through education. These new options must be compared and contrasted with current treatments, including immunomodulatory agents, to ultimately form an individualized treatment strategy for each MS patient.

Upon Completion of this activity, participants will be able to:

  • Examine the mechanisms of action, efficacy, and safety of current and emerging multiple sclerosis (MS) treatments to develop individualized therapies and their effect on staging and sequencing

  • Analyze strategies for identifying MS earlier in the disease course with the goal of initiating treatment earlier and promoting disease inactivity

  • Discuss patient, disease, and treatment characteristics that factor into individualized MS treatment selection and considerations for predicting treatment response and identifying when to switch therapies

  • Apply newer MRI criteria and other prognostic measures to improve diagnosis and initiate DMD therapy earlier in the course of MS

  • Analyze treatment options and strategies for MS patients who have had an inadequate response to previous treatment regimens

  • Evaluate modifiable risk factors and ongoing evaluations to improve relapsing MS care, as well as evidenced based strategies to manage common treatment-related side effects

Faculty: Robert Bermel, MD
Staff Neurologist and Medical Director
Mellen Center for MS Treatment and Research
Cleveland Clinic


Dr. Bermel serves as a consultant to Biogen, Genentech, Genzyme and Novartis. He receives research support from Biogen and Genentech. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

The National Association of Managed Care Physicians designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity and turn in a validation form will receive up to 1 credit in continuing nursing education.

The American Board of Managed Care Nurses has approved this activity for a maximum of 1 contact hour towards CMCN recertification.

This presentation is supported by educational grants from
 AbbVie Inc, Sanofi Genzyme, and Teva Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.